Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Unknown 2Completed 2Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Carcinoma, Hepatocellular 38Carcinoma, Non-Small-Cell Lung 23Stomach Neoplasms 19Nasopharyngeal Carcinoma 19Triple Negative Breast Neoplasms 18Esophageal Squamous Cell Carcinoma 17Esophageal Neoplasms 16Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Colorectal Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 8Sarcoma 6Recurrence 6Neoplasm Metastasis 6Melanoma 6Liver Neoplasms 6Cholangiocarcinoma 6Lung Neoplasms 5Hodgkin Disease 5Biliary Tract Neoplasms 5Osteosarcoma 4Neoplasms 4Locally Advanced Gastric Cancer 4Advanced Gastric Cancer 4Rectal Neoplasms 3Nasopharyngeal Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Urinary Bladder Neoplasms 2

Interventions

Gemcitabine 58Cisplatin 41Capecitabine 27Oxaliplatin 25durvalumab 16Fluorouracil 16Leucovorin 15S 1 (combination) 11lenvatinib 10Nivolumab 10Irinotecan 10pembrolizumab 8apatinib 8Immune Checkpoint Inhibitors 7130-nm albumin-bound paclitaxel 7tremelimumab 6Bevacizumab 6camrelizumab 5Trastuzumab 5Drug Therapy 5Blood Specimen Collection 5Albumin-Bound Paclitaxel 5tislelizumab 4irinotecan sucrosofate 4Taxes 4Liquid Biopsy 4Folfox protocol 4toripalimab 3surufatinib 3gemcitabine-oxaliplatin regimen 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Biliary Tract Neoplasms × camrelizumab × Clear all
NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Peking Union Medical College Hospital

Phase 2 Not yet recruiting
65 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT04720131 2024-01-30

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Beijing Friendship Hospital

Phase 2 Completed
28 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT05742750 2023-02-24

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Sun Yat-sen University

Phase 1/2 Unknown
48 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT04642664 2021-06-03

ACABC

Peking Union Medical College Hospital

Phase 2 Completed
22 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT03311789 2017-10-17

Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs

Chinese PLA General Hospital

Phase 1/2 Unknown
30 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡